Apellis Pharmaceuticals, Inc. short interest in 2022
In 2022, Apellis Pharmaceuticals, Inc.'s disclosed short interest ran from 7.15% of shares outstanding on 14 Jan 2022 to 8.30% on 30 Dec 2022, a change of +1.15 percentage points. The year's high was 9.39% on 15 Nov 2022 and its low 7.15% on 14 Jan 2022, averaging 8.41% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.90 days on 15 Jun 2022. Full history: Apellis Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 7.15% (14 Jan 2022)
- End of year
- 8.30% (30 Dec 2022)
- Change
- +1.15 pp
- High
- 9.39% (15 Nov 2022)
- Low
- 7.15% (14 Jan 2022)
- Average
- 8.41%
- Highest days to cover
- 11.90 (15 Jun 2022)
- SEC filings marked
- 5
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 7.15% | 7.67 | results (8-K) |
| 31 Jan 2022 | 8.36% | 6.16 | |
| 15 Feb 2022 | 7.98% | 9.15 | |
| 28 Feb 2022 | 7.87% | 10.55 | 10-K filed |
| 15 Mar 2022 | 7.32% | 6.29 | |
| 31 Mar 2022 | 8.35% | 3.81 | |
| 14 Apr 2022 | 8.99% | 6.87 | |
| 29 Apr 2022 | 8.28% | 9.74 | |
| 13 May 2022 | 8.59% | 7.13 | 10-Q filed |
| 31 May 2022 | 8.42% | 9.24 | |
| 15 Jun 2022 | 8.59% | 11.90 | |
| 30 Jun 2022 | 9.20% | 9.39 | |
| 15 Jul 2022 | 8.79% | 11.13 | |
| 29 Jul 2022 | 9.23% | 5.61 | |
| 15 Aug 2022 | 7.27% | 7.24 | 10-Q filed |
| 31 Aug 2022 | 7.62% | 6.45 | |
| 15 Sep 2022 | 8.28% | 5.23 | |
| 30 Sep 2022 | 8.94% | 7.46 | |
| 14 Oct 2022 | 7.99% | 5.42 | |
| 31 Oct 2022 | 8.86% | 11.04 | |
| 15 Nov 2022 | 9.39% | 4.48 | 10-Q filed |
| 30 Nov 2022 | 8.92% | 6.15 | |
| 15 Dec 2022 | 9.09% | 9.65 | |
| 30 Dec 2022 | 8.30% | 10.68 |
See also: Apellis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.